ElectroCore Inc. (ECOR) stock rises during pre-market trading. Here’s the update

REVB Stock
REVB Stock

ElectroCore Inc. (NASDAQ: ECOR) stock declined by 0.82% at the last close whereas the ECOR stock-price gains by 5.87% in the pre-market trading session. ElectroCore is an advertising bioelectronic medicine firm aimed at improving patient care with their non-invasive vagus nerve stimulation therapy system, which was initially designed to treat a variety of neurological diseases.

>> 7 Top Picks for the Post-Pandemic Economy << 

ECOR stock’ Significant Event

The ElectroCore executive team will offer a corporate briefing at the HC Wainwright 23rd Annual Global Investment Conference, according to the company. Starting from today till Sep’15, 2021, the conference will be held virtually.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Read More

Recent Development

Red One Medical Devices, LLC has signed a reseller deal with ElectroCore (Red One). The collaboration will boost electroCore’s gammaCore platform’s accessibility in the federal sector.

Red One is a Service-Disabled Veteran-Owned Small Business (SDVOSB) that provides medical and pharmaceutical products and services to VA and DoD hospitals, as well as ensuring adherence with contracting rules and offering logistical alternatives directly attached to government contracting portals like ECAT, GSA, DAPA, BPA, and DIBBS.

Charles Pollak, President of Red One said that they are thrilled to work with electroCore as a VA and DoD private sector collaborator for medical advancement. Thousands of service personnel, family members, and veterans may benefit from their gammaCore therapy. With over 20% of ex-service members, particularly those from the post-9/11 combat veteran cohort, suffer from painful and severe headaches. They’re excited to work with electroCore to make the therapy more widely available in the federal marketplace.

Dan Goldberger, Chief Executive Officer of electroCore commented,

Collaborating with Red One will help electroCore’s therapy gain traction in the government market. The agreement allows electroCore access to a number of contractual portals, making gammaCore therapy more accessible to veterans and active military personnel. They’ve only scratched the surface of the assistance that they can provide to VA and DoD veterans, troops, and family members, and they’re proud to join with an SDVOSB to make gammaCore therapy more broadly accessible to those veterans and active-duty military who can get advantage from it.


Please enter your comment!
Please enter your name here